The phase ll clinical trial of Youngene's leading candidate YG1699 has been carried out in the United States.The kick-offmeeting of clinical research center was successfuly held in San Diego on June 8,2021.The recruitment and screeningof subjects are in progress, and the first subject will begin to receive YG1699 treatment in early July.This study will treatpatients with type l diabetes.